Amanda Mocroft

Summary

Affiliation: University College London
Country: UK

Publications

  1. doi request reprint Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients
    Amanda Mocroft
    HIV Epidemiology and Biostatistics Group, Research Department of Infection and Population Health, Division of Population Health, University College London Medical School, Royal Free Campus, London, UK
    AIDS 24:1667-78. 2010
  2. ncbi request reprint A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe
    A Mocroft
    Department of Infection and Population Health, University College London, Rowland Hill St, London, NW3 2PF, UK
    Infection 42:757-62. 2014
  3. pmc Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE)
    Amanda Mocroft
    Department of Infection and Population Health, University College London, London, United Kingdom
    PLoS Med 10:e1001510. 2013
  4. pmc Benchmarking HIV health care: from individual patient care to health care evaluation. An example from the EuroSIDA study
    Daria N Podlekareva
    Copenhagen HIV Programme, University of Copenhagen, Copenhagen, Denmark
    BMC Infect Dis 12:229. 2012
  5. doi request reprint CD4 cell count and viral load-specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use
    Amanda Mocroft
    HIV Epidemiology and Biostatistics Group, Research Department of Infection and Population Health, University College London, London, UK
    AIDS 27:907-18. 2013
  6. doi request reprint The clinical benefits of antiretroviral therapy in severely immunocompromised HIV-1-infected patients with and without complete viral suppression
    Amanda Mocroft
    Research Department of Infection and Population Health, University College London, London, UK
    Antivir Ther 17:1291-300. 2012
  7. doi request reprint Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy
    Amanda Mocroft
    Research Department of Infection and Population Health, University College London Medical School, London, UK
    Antivir Ther 15:563-70. 2010
  8. pmc Haemoglobin and anaemia in the SMART study
    Amanda Mocroft
    University College Medical School, London, UK
    Antivir Ther 16:329-37. 2011
  9. doi request reprint Serious fatal and nonfatal non-AIDS-defining illnesses in Europe
    Amanda Mocroft
    Research Department of Infection and Population Health, University College Medical School, London, UK
    J Acquir Immune Defic Syndr 55:262-70. 2010
  10. ncbi request reprint Incidence of abacavir hypersensitivity reactions in euroSIDA
    Wendy P Bannister
    Royal Free and University College Medical School, London, UK
    Antivir Ther 13:687-96. 2008

Collaborators

Detail Information

Publications45

  1. doi request reprint Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients
    Amanda Mocroft
    HIV Epidemiology and Biostatistics Group, Research Department of Infection and Population Health, Division of Population Health, University College London Medical School, Royal Free Campus, London, UK
    AIDS 24:1667-78. 2010
    ..Chronic kidney disease (CKD) in HIV-positive persons might be caused by both HIV and traditional or non-HIV-related factors. Our objective was to investigate long-term exposure to specific antiretroviral drugs and CKD...
  2. ncbi request reprint A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe
    A Mocroft
    Department of Infection and Population Health, University College London, Rowland Hill St, London, NW3 2PF, UK
    Infection 42:757-62. 2014
    ..4 %), and least common in Eastern Europe (2/31 clinics; 6.5 %; p < 0.0001). Over one-third of the participating clinics in this survey were using ATRIPLA as first-line antiretroviral therapy, despite EMA recommendations. ..
  3. pmc Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE)
    Amanda Mocroft
    Department of Infection and Population Health, University College London, London, United Kingdom
    PLoS Med 10:e1001510. 2013
    ..Few studies have monitored late presentation (LP) of HIV infection over the European continent, including Eastern Europe. Study objectives were to explore the impact of LP on AIDS and mortality...
  4. pmc Benchmarking HIV health care: from individual patient care to health care evaluation. An example from the EuroSIDA study
    Daria N Podlekareva
    Copenhagen HIV Programme, University of Copenhagen, Copenhagen, Denmark
    BMC Infect Dis 12:229. 2012
    ..State-of-the-art care involving the utilisation of multiple health care interventions is the basis for an optimal long-term clinical prognosis for HIV-patients. We evaluated health care for HIV patients based on four key indicators...
  5. doi request reprint CD4 cell count and viral load-specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use
    Amanda Mocroft
    HIV Epidemiology and Biostatistics Group, Research Department of Infection and Population Health, University College London, London, UK
    AIDS 27:907-18. 2013
    ..The aim of this study was to investigate the CD4 cell count and viral load-specific rates of fatal and nonfatal AIDS and non-AIDS events according to current antiretrovirals...
  6. doi request reprint The clinical benefits of antiretroviral therapy in severely immunocompromised HIV-1-infected patients with and without complete viral suppression
    Amanda Mocroft
    Research Department of Infection and Population Health, University College London, London, UK
    Antivir Ther 17:1291-300. 2012
    ..The aim of this study was to determine whether there is a protective effect of combination antiretroviral therapy (cART) on the development of clinical events in patients with ongoing severe immunosuppression...
  7. doi request reprint Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy
    Amanda Mocroft
    Research Department of Infection and Population Health, University College London Medical School, London, UK
    Antivir Ther 15:563-70. 2010
    ..Patients receiving combination antiretroviral therapy (cART) might continue treatment with a virologically failing regimen. We sought to identify annual change in CD4(+) T-cell count according to levels of viraemia in patients on cART...
  8. pmc Haemoglobin and anaemia in the SMART study
    Amanda Mocroft
    University College Medical School, London, UK
    Antivir Ther 16:329-37. 2011
    ..Data from randomized trials on the development of anaemia after interruption of therapy are not well-described...
  9. doi request reprint Serious fatal and nonfatal non-AIDS-defining illnesses in Europe
    Amanda Mocroft
    Research Department of Infection and Population Health, University College Medical School, London, UK
    J Acquir Immune Defic Syndr 55:262-70. 2010
    ..Little is known about the incidence and risk factors for serious non-AIDS-defining events...
  10. ncbi request reprint Incidence of abacavir hypersensitivity reactions in euroSIDA
    Wendy P Bannister
    Royal Free and University College Medical School, London, UK
    Antivir Ther 13:687-96. 2008
    ..The aim of the study was to investigate the incidence of abacavir-related hypersensitivity reaction (HSR) and associated deaths in EuroSIDA HIV-1-infected patients...
  11. doi request reprint Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study
    Alessandro Cozzi-Lepri
    Research Department of Infection and Population Health, Royal Free and University College Medical School, London, UK
    AIDS 22:2187-98. 2008
    ..To investigate the relationship between detection of HIV drug resistance by 2 years from starting antiretroviral therapy and the subsequent risk of progression to AIDS and death...
  12. ncbi request reprint Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia
    Amanda Mocroft
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK
    AIDS 20:1141-50. 2006
    ..It is unknown if the CD4 cell count response differs according to antiretroviral drugs used in combination antiretroviral therapy (cART) in patients with maximal virological suppression [viral load (VL) < 50 copies/ml]...
  13. ncbi request reprint Chronic renal failure among HIV-1-infected patients
    Amanda Mocroft
    Royal Free Centre for HIV Medicine, and Department of Primary Care and Population Sciences, Royal Free and University College Medical Schools, Royal Free Campus, Rowland Hill Street, London, UK
    AIDS 21:1119-27. 2007
    ..The role of exposure to antiretrovirals in chronic renal failure (CRF) is not well understood. Glomerular filtration rates (GFR) are estimated using the Cockcroft-Gault (CG) or Modification of Diet in Renal Disease (MDRD) equations...
  14. doi request reprint Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA
    Wendy P Bannister
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    AIDS 22:367-76. 2008
    ..To compare virological outcome and genotypic resistance profiles in HIV-1-infected patients starting non-nucleoside reverse transcriptase inhibitor (NNRTI)-containing regimens...
  15. doi request reprint Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure?
    Joanne Reekie
    HIV Epidemiology and Biostatistics Group, Research Department of Infection and Population Health, Royal Free and University College Medical School, London, UK
    AIDS 22:2381-90. 2008
    ..To investigate whether HIV-infected patients on a stable and fully suppressive combination antiretroviral therapy (cART) regimen could safely be monitored less often than the current recommendations of every 3 months...
  16. ncbi request reprint HIV-1 subtypes and response to combination antiretroviral therapy in Europe
    Wendy P Bannister
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    Antivir Ther 11:707-15. 2006
    ..Antiretroviral drugs have predominantly been developed in Western Europe/North America on the basis of the most prevalent subtype, B. However, non-B subtypes are increasingly spreading worldwide...
  17. ncbi request reprint Virological rebound after suppression on highly active antiretroviral therapy
    Amanda Mocroft
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    AIDS 17:1741-51. 2003
    ..Treatment-naive patients were at a lower risk of rebound, but among drug-experienced patients, those who added new nucleosides had a lower risk of rebound, as were patients with a good immunological response...
  18. ncbi request reprint Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score
    Amanda Mocroft
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    AIDS 21:1867-75. 2007
    ..To derive and validate a clinically applicable prognostic score for predicting short-term disease progression in HIV-infected patients taking combination antiretroviral therapy (cART)...
  19. ncbi request reprint Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naive and -experienced HIV-infected patients with high and low CD4+ T-cell counts
    Amanda Mocroft
    Royal Free and University College Medical School, London, UK
    Antivir Ther 12:325-33. 2007
    ....
  20. doi request reprint Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study
    Wendy P Bannister
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, United Kingdom
    J Acquir Immune Defic Syndr 48:324-33. 2008
    ..To investigate prevalence of transmitted drug-resistant human immunodeficiency virus (TDR) and factors associated with TDR and to compare virological and CD4 count response to combination antiretroviral therapy...
  21. ncbi request reprint Causes of death in HIV infection: the key determinant to define the clinical response to anti-HIV therapy
    Amanda Mocroft
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    AIDS 18:2333-7. 2004
    ..Compared with homosexual individuals, IDU had an increased incidence of new AIDS/death, but only for non-HIV deaths. There is an urgent need to define and standardize causes of death in observational studies...
  22. ncbi request reprint Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection?
    Amanda Mocroft
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    Antivir Ther 10:779-90. 2005
    ..Little information to address this concern is available from clinical trials as patients with HCV are often excluded...
  23. ncbi request reprint The role of antiretroviral therapy in the incidence of pancreatitis in HIV-positive individuals in the EuroSIDA study
    Colette J Smith
    Royal Free and University College Medical School, London, UK
    AIDS 22:47-56. 2008
    ..This study investigated the incidence of pancreatitis and its association with antiretroviral therapy (ART), focussing on stavudine and didanosine...
  24. pmc Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study
    Rebecca K Lodwick
    HIV Epidemiology and Biostatistics Group, Research Department of Infection and Population Health, UCL Medical School, Royal Free Campus, London, UK
    Lancet 376:340-5. 2010
    ..We aimed to examine this by analysis of pooled data from industrialised countries...
  25. pmc Regional differences in AIDS and non-AIDS related mortality in HIV-positive individuals across Europe and Argentina: the EuroSIDA study
    Joanne Reekie
    Medical School, University College London, London, United Kingdom
    PLoS ONE 7:e41673. 2012
    ..This analysis aimed to establish whether there are regional differences in the mortality rate of HIV-positive individuals across Europe, and Argentina...
  26. doi request reprint Fatal and nonfatal AIDS and non-AIDS events in HIV-1-positive individuals with high CD4 cell counts according to viral load strata
    Joanne Reekie
    University College London Medical School, London, UK
    AIDS 25:2259-68. 2011
    ..9  copies/ml) and high (≥ 10000  copies/ml)...
  27. ncbi request reprint The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003: the EuroSIDA Study
    Amanda Mocroft
    Royal Free Centre for HIV Medicine, Royal Free and University College Medical School, London, United Kingdom
    Cancer 100:2644-54. 2004
    ....
  28. ncbi request reprint Regional changes over time in initial virologic response rates to combination antiretroviral therapy across Europe
    Wendy P Bannister
    Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    J Acquir Immune Defic Syndr 42:229-37. 2006
    ..Regional variations may identify differences in available antiretroviral drugs or patient management...
  29. ncbi request reprint Is there evidence for an increase in the death rate from liver-related disease in patients with HIV?
    Amanda Mocroft
    Royal Free Centre for HIV Medicine and Dept Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    AIDS 19:2117-25. 2005
    ..Increases in deaths due to liver-related disease (LRD) among HIV-infected individuals have been reported although the influence of combination antiretroviral therapy (cART) on LRD is controversial...
  30. ncbi request reprint Limited but increasing use of treatment for hepatitis C across Europe in patients coinfected with HIV and hepatitis C
    Amanda Mocroft
    Royal Free Centre for HIV Medicine, Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
    Scand J Infect Dis 38:1092-7. 2006
    ..6 - 6.1) to 32.6 per 1000 PYFU at/after 2004 (95% CI 22.5 - 42.7). Although prescription of HCV therapy is increasing in HIV-coinfected patients, it remains infrequent and variable across regions of Europe...
  31. ncbi request reprint Decline in esophageal candidiasis and use of antimycotics in European patients with HIV
    Amanda Mocroft
    Royal Free Centre for HIV Medicine and Dept Primary Care and Population Sciences, Royal Free and University College Medical School, London, United Kingdom
    Am J Gastroenterol 100:1446-54. 2005
    ....
  32. doi request reprint Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies
    Joanne Reekie
    University College London Medical School, London, UK
    Cancer 116:5306-15. 2010
    ..However, conflicting data have been reported on the relationship between immunodeficiency and the development of some non-AIDS-defining malignancies...
  33. pmc Interruption of antiretroviral therapy is associated with increased plasma cystatin C
    Amanda Mocroft
    University College London Medical School, London, UK
    AIDS 23:71-82. 2009
    ....
  34. ncbi request reprint Brief report: two-year outcome of a multidrug regimen in patients who did not respond to a protease inhibitor regimen
    Mike Youle
    Royal Free Centre for HIV Medicine, Royal Free and University College Medical School, London, United Kingdom
    J Acquir Immune Defic Syndr 29:58-61. 2002
    ..Thus, a substantial proportion of patients who had failed to respond virologically to PI-containing regimens can achieve profound and sustained virologic suppression with a multidrug regimen...
  35. pmc Hepatitis B and C co-infection are independent predictors of progressive kidney disease in HIV-positive, antiretroviral-treated adults
    Amanda Mocroft
    Research Department of Infection and Population Health, University College London Medical School, London, United Kingdom
    PLoS ONE 7:e40245. 2012
    ..Future studies should validate the relationship between HCV viremia and CKD. Trial registration: ClinicalTrials.gov NCT00027352; NCT00004978...
  36. ncbi request reprint Deteriorating renal function and clinical outcomes in HIV-positive persons
    Amanda Mocroft
    aDepartment of Infection and Population Health, University College London, London, UK bCopenhagen HIV Program cDepartment of Infectious Diseases, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark dUniversity Hospital of Infectious Diseases, Zagreb, Croatia eDepartment of Health Sciences, Institute of Infectious Diseases, Milan, Italy fBelarus State Medical University, Minsk, Belarus gHospital Clinic i Provincial, Barcelona, Spain hInstitute of Tropical Medicine, Antwerp, Belgium iUllevål University Hospital, Ulleval, Norway Study group listed in appendix
    AIDS 28:727-37. 2014
    ....
  37. doi request reprint Increased incidence of antiretroviral drug discontinuation among patients with viremic hepatitis C virus coinfection and high hyaluronic acid, a marker of liver fibrosis
    Daniel Grint
    aDepartment of Infection and Population Health, University College London, London, UK bCopenhagen HIV Programme, University of Copenhagen cDepartment of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark dDepartment of Medicine I, University of Bonn, Bonn, Germany eDepartment of Infectious Diseases, Saint Pierre Hospital, Brussels, Belgium fInfectious Diseases Department, Gomel State Medical University, Gomel, Belarus gDepartment of Infectious Diseases, Medical University, Wroclaw, Poland hInfectious Diseases Department, Odense University Hospital, Odense, Denmark
    AIDS 28:577-87. 2014
    ..This study aimed to determine the risk of antiretroviral drug discontinuation among HCV/HIV coinfected patients...
  38. ncbi request reprint Antiretroviral therapy, immune suppression and renal impairment in HIV-positive persons
    Lene Ryom
    aCopenhagen HIV Programme and Epidemiklinikken, Copenhagen University Hospital Rigshospitalet, University of Copenhagen, Copenhagen, Denmark bResearch Department of Infection and Population Health, UCL, London, United Kingdom
    Curr Opin HIV AIDS 9:41-7. 2014
    ..The purpose of this article is to review recent literature on antiretroviral treatment (ART) and immune suppression as risk factors for renal impairment in HIV-positive persons, and to discuss pending research questions within this field...
  39. ncbi request reprint Highly active antiretroviral therapy and cervical intraepithelial neoplasia
    Antonia L Moore
    Center for HIV Medicine, Royal Free Hospital, London, UK
    AIDS 16:927-9. 2002
    ..Such studies will provide the basis for guidelines for monitoring CIN in HIV-positive women in the HAART era...
  40. ncbi request reprint Starting highly active antiretroviral therapy: why, when and response to HAART
    Amanda Mocroft
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Royal Free Campus, Rowland Hill St, London NW3 2PF, UK
    J Antimicrob Chemother 54:10-3. 2004
    ..There has been a switch to more conservative therapy recently, given concerns about toxicities and the difficulties of adhering to a complicated regimen long term...
  41. ncbi request reprint Prognostic Value of Vitamin D Level for All-cause Mortality, and Association With Inflammatory Markers, in HIV-infected Persons
    Leah Shepherd
    Department of Infection and Population Health, University College London Medical School, London, United Kingdom
    J Infect Dis 210:234-43. 2014
    ..We aimed to identify the prognostic value of 25(OH)D for AIDS, non-AIDS-defining events and death, and its association with immunological/inflammatory markers...
  42. pmc Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D study
    David A Kamara
    Research Dept, of Infection and Population Health, University College London, London, United Kingdom
    BMC Nephrol 15:51. 2014
    ..73 m2 (using Cockcroft Gault) in the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study from 2004 to 2011...
  43. pmc Feasibility and effectiveness of indicator condition-guided testing for HIV: results from HIDES I (HIV indicator diseases across Europe study)
    Ann K Sullivan
    Directorate of Sexual Health and HIV Medicine, Chelsea and Westminster NHS Foundation Trust, London, United Kingdom
    PLoS ONE 8:e52845. 2013
    ..A strategy is being developed in collaboration with ECDC and WHO Europe to guide the implementation of this novel public health initiative across Europe...
  44. pmc Cohort Profile: Antiretroviral Therapy Cohort Collaboration (ART-CC)
    Margaret T May
    School of Social and Community Medicine, University of Bristol, Bristol, UK, UPMC Univ Paris 06, UMR_S 943, F 75013, Paris, France INSERM, UMR_S 943, F 75013, Paris, France AP HP, Hopital Pitie Salpetriere, Service des Maladies Infectieuses et Tropicales, F 75013, Paris, France, Yale University School of Medicine, New Haven, CT, USA, VA Connecticut Healthcare System, West Haven, CT, USA, Academisch Medisch Centrum bij de universiteit van Amsterdam, Amsterdam, The Netherlands, University Hospital Lausanne, Lausanne, Switzerland, Clinic of Infectious Diseases and Tropical Medicine, San Paolo Hospital, University of Milan, Italy, Centre d Estudis Epidemiològics sobre ITS VIH SIDA de Catalunya, Badalona, Spain, Division of Epidemiology and Population Health, British Columbia Centre for Excellence in HIV AIDS, Vancouver, Canada, Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada, Research Department of Infection and Population Health, UCL Medical School, London, UK
    Int J Epidemiol 43:691-702. 2014
    ..External collaboration is welcomed. Details of contacts are given on the ART-CC website (www.art-cohort-collaboration.org). ..
  45. doi request reprint Biomarkers of impaired renal function
    Frank A Post
    King s College London School of Medicine, London, UK
    Curr Opin HIV AIDS 5:524-30. 2010
    ..Several biomarkers are available for monitoring renal function, although no consensus exists on how best to apply these tools in HIV infection. This review describes recent findings for the more common renal biomarkers...